Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Total Valuation
JW (Cayman) Therapeutics Co. Ltd. has a market cap or net worth of HK$1.79B. The enterprise value is HK$888.07M.
Market CapHK$1.79B
Enterprise ValueHK$888.07M
Share Statistics
JW (Cayman) Therapeutics Co. Ltd. has 416,473,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding416,473,240
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
JW (Cayman) Therapeutics Co. Ltd.’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -28.86%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-28.86%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee563.05K
Profits Per Employee-2.10M
Employee Count281
Asset Turnover0.09
Inventory Turnover2.59
Valuation Ratios
The current PE Ratio of JW (Cayman) Therapeutics Co. Ltd. is ―. JW (Cayman) Therapeutics Co. Ltd.’s PEG ratio is 0.04.
PE Ratio―
PS Ratio3.14
PB Ratio0.43
Price to Fair Value0.43
Price to FCF-1.43
Price to Operating Cash Flow-8.81
PEG Ratio0.04
Income Statement
In the last 12 months, JW (Cayman) Therapeutics Co. Ltd. had revenue of 158.22M and earned -590.62M in profits. Earnings per share was -1.43.
Revenue158.22M
Gross Profit77.32M
Operating Income-459.28M
Pretax Income-590.62M
Net Income-590.62M
EBITDA-381.58M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -200.13M and capital expenditures -2.60M, giving a free cash flow of -202.73M billion.
Operating Cash Flow-200.13M
Free Cash Flow-202.73M
Free Cash Flow per Share-0.49
Dividends & Yields
JW (Cayman) Therapeutics Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.46
52-Week Price Change149.71%
50-Day Moving Average5.05
200-Day Moving Average2.77
Relative Strength Index (RSI)42.38
Average Volume (3m)3.25M
Important Dates
JW (Cayman) Therapeutics Co. Ltd. upcoming earnings date is Mar 25, 2026, TBA (Confirmed).
Last Earnings DateAug 27, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
JW (Cayman) Therapeutics Co. Ltd. as a current ratio of 1.74, with Debt / Equity ratio of 36.13%
Current Ratio1.74
Quick Ratio1.67
Debt to Market Cap0.77
Net Debt to EBITDA0.88
Interest Coverage Ratio-37.58
Taxes
In the past 12 months, JW (Cayman) Therapeutics Co. Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
JW (Cayman) Therapeutics Co. Ltd. EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.47.
EV to Sales1.03
EV to EBITDA-0.43
EV to Free Cash Flow-0.47
EV to Operating Cash Flow-0.49
Balance Sheet
JW (Cayman) Therapeutics Co. Ltd. has HK$647.04M in cash and marketable securities with HK$422.40M in debt, giving a net cash position of HK$274.58M billion.
Cash & Marketable SecuritiesHK$647.04M
Total DebtHK$422.40M
Net CashHK$274.58M
Net Cash Per ShareHK$0.66
Tangible Book Value Per ShareHK$1.42
Margins
Gross margin is 48.87%, with operating margin of -290.28%, and net profit margin of -373.30%.
Gross Margin48.87%
Operating Margin-290.28%
Pretax Margin-373.30%
Net Profit Margin-373.30%
EBITDA Margin-241.17%
EBIT Margin-290.13%
Analyst Forecast
The average price target for JW (Cayman) Therapeutics Co. Ltd. is HK$6.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$6.00
Price Target Upside38.89% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast2.45%
EPS Growth Forecast2.58%